LICENCE DEAL PROVES KEY
Avacta’s drug development division will hit the big time once Avacta has signed a licence deal with a big pharmaceutical firm.
This could be worth between £14m to £28m in an upfront payment, followed by other payments as the drugs roll out.
Avacta hopes to get a licence deal in the next couple of years.
The other side of the business is the use of Affimers in diagnostics and this should make a profit in three years’ time.
Dr Smith said: “We currently have a £20m market cap. We could see an improvement to our market cap of between ten and twenty-fold.”